交易 Arcturus Therapeutics Holdings Inc. - ARCT CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.09 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 20% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Jun 29, 2022 | 15.37 | 0.54 | 3.64% | 14.83 | 15.60 | 14.44 |
Jun 28, 2022 | 15.04 | -0.93 | -5.82% | 15.97 | 16.21 | 14.77 |
Jun 27, 2022 | 16.14 | 0.75 | 4.87% | 15.39 | 16.39 | 15.22 |
Jun 24, 2022 | 15.87 | -0.21 | -1.31% | 16.08 | 16.42 | 14.99 |
Jun 23, 2022 | 15.93 | 0.85 | 5.64% | 15.08 | 16.08 | 14.88 |
Jun 22, 2022 | 15.36 | 1.52 | 10.98% | 13.84 | 16.06 | 13.84 |
Jun 21, 2022 | 14.51 | 0.68 | 4.92% | 13.83 | 15.47 | 13.83 |
Jun 17, 2022 | 13.39 | 0.89 | 7.12% | 12.50 | 14.16 | 12.50 |
Jun 16, 2022 | 12.21 | -0.26 | -2.09% | 12.47 | 12.63 | 11.65 |
Jun 15, 2022 | 13.22 | 0.38 | 2.96% | 12.84 | 13.45 | 12.27 |
Jun 14, 2022 | 12.85 | -0.43 | -3.24% | 13.28 | 13.28 | 12.31 |
Jun 13, 2022 | 13.13 | -1.10 | -7.73% | 14.23 | 14.23 | 12.47 |
Jun 10, 2022 | 15.03 | -1.42 | -8.63% | 16.45 | 16.75 | 14.66 |
Jun 9, 2022 | 17.07 | -1.92 | -10.11% | 18.99 | 18.99 | 16.99 |
Jun 8, 2022 | 19.40 | 0.14 | 0.73% | 19.26 | 20.15 | 19.17 |
Jun 7, 2022 | 19.43 | 1.48 | 8.25% | 17.95 | 19.56 | 17.74 |
Jun 6, 2022 | 18.46 | -1.51 | -7.56% | 19.97 | 20.59 | 17.57 |
Jun 3, 2022 | 19.89 | 1.99 | 11.12% | 17.90 | 19.94 | 17.90 |
Jun 2, 2022 | 18.77 | 1.00 | 5.63% | 17.77 | 19.11 | 17.77 |
Jun 1, 2022 | 18.37 | -0.88 | -4.57% | 19.25 | 20.51 | 17.93 |
Arcturus Therapeutics Holdings Inc. Events
時間(協調世界時) (UTC) | 國家 | 事件 |
---|---|---|
No events scheduled |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
总收入 | 12.359 | 9.539 | 20.789 | 15.753 | 12.998 |
收入 | 12.359 | 9.539 | 20.789 | 15.753 | 12.998 |
总营业费用 | 215.211 | 81.063 | 46.302 | 37.564 | 23.49 |
销售/一般/行政费用,总计 | 41.451 | 23.217 | 12.662 | 20.582 | 7.572 |
研究与开发 | 173.76 | 57.846 | 33.64 | 16.982 | 15.918 |
营业收入 | -202.852 | -71.524 | -25.513 | -21.811 | -10.492 |
利息收入(费用),非经营净值 | -0.822 | -0.624 | -0.478 | 0.026 | -0.061 |
其他,净值 | 0 | -0.348 | |||
税前净收入 | -203.674 | -72.148 | -25.991 | -21.785 | -10.901 |
税后净收入 | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
未计算非常项目前的净收益 | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
净收入 | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
普通股股东可获收益 (不含非经常性项目) | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
普通股股东可获收益 (含非經常性項目) | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
摊薄净收入 | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
摊薄后加权平均股 | 26.317 | 20.305 | 12.069 | 10.069 | 3.087 |
扣除特别项目的每股摊薄盈利 | -7.73926 | -3.55321 | -2.15353 | -2.16357 | -3.53158 |
每股正常摊薄盈利 | -7.73926 | -3.55321 | -2.15353 | -2.16357 | -3.53158 |
非常规项目总计 | 0 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
总收入 | 5.244 | 5.794 | 2.437 | 2.001 | 2.127 |
收入 | 5.244 | 5.794 | 2.437 | 2.001 | 2.127 |
总营业费用 | 55.623 | 43.439 | 56.258 | 55.721 | 59.793 |
销售/一般/行政费用,总计 | 10.73 | 10.806 | 10.86 | 10.042 | 9.743 |
研究与开发 | 44.893 | 32.633 | 45.398 | 45.679 | 50.05 |
营业收入 | -50.379 | -37.645 | -53.821 | -53.72 | -57.666 |
利息收入(费用),非经营净值 | -0.79 | -1.018 | -0.263 | -0.861 | 1.32 |
税前净收入 | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
税后净收入 | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
未计算非常项目前的净收益 | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
净收入 | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
普通股股东可获收益 (不含非经常性项目) | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
普通股股东可获收益 (含非經常性項目) | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
摊薄净收入 | -51.169 | -38.663 | -54.084 | -54.581 | -56.346 |
摊薄后加权平均股 | 26.376 | 26.362 | 26.338 | 26.323 | 26.243 |
扣除特别项目的每股摊薄盈利 | -1.93998 | -1.46662 | -2.05346 | -2.07351 | -2.14709 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -1.93998 | -1.46662 | -2.05346 | -2.07351 | -2.14709 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
流动资产总额 | 378.961 | 467.789 | 74.29 | 41.828 | 50.868 |
现金和短期投资 | 370.492 | 462.895 | 71.353 | 36.709 | 48.573 |
现金等价物 | 370.492 | 462.895 | 71.353 | 36.709 | 24.965 |
短期投资 | 0 | 23.608 | |||
应收账款总额,净额 | 3.367 | 2.125 | 2.179 | 4.481 | 0.48 |
Accounts Receivable - Trade, Net | 3.367 | 2.125 | 2.179 | 4.481 | 0.48 |
Prepaid Expenses | 5.102 | 2.769 | 0.758 | 0.638 | 0.704 |
Other Current Assets, Total | 0 | 1.111 | |||
Total Assets | 392.814 | 476.456 | 82.143 | 44.198 | 52.024 |
Property/Plant/Equipment, Total - Net | 11.261 | 8.56 | 7.483 | 1.975 | 1.049 |
Property/Plant/Equipment, Total - Gross | 15.517 | 11.623 | 9.664 | 2.016 | |
Accumulated Depreciation, Total | -4.256 | -3.063 | -2.181 | -0.967 | |
Other Long Term Assets, Total | 2.077 | 0.107 | 0.107 | 0.107 | 0.107 |
Total Current Liabilities | 99.537 | 49.521 | 21.324 | 12.577 | 11.04 |
Accounts Payable | 10.058 | 10.774 | 5.793 | 2.398 | 1.79 |
Accrued Expenses | 23.523 | 19.389 | 4.384 | 3.907 | 1.812 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 43.482 | 18.108 | 11.147 | 6.272 | 7.438 |
Total Liabilities | 164.603 | 79.903 | 56.351 | 30.556 | 18.23 |
Total Long Term Debt | 40.633 | 13.845 | 14.995 | 9.911 | 0 |
Other Liabilities, Total | 24.433 | 16.537 | 20.032 | 8.068 | 7.19 |
Total Equity | 228.211 | 396.553 | 25.792 | 13.642 | 33.794 |
Common Stock | 0.026 | 0.026 | 0.015 | 0.214 | 0.212 |
Additional Paid-In Capital | 575.675 | 540.343 | 97.445 | 58.302 | 56.674 |
Retained Earnings (Accumulated Deficit) | -347.49 | -143.816 | -71.668 | -44.874 | -23.089 |
Other Equity, Total | 0 | -0.003 | |||
Total Liabilities & Shareholders’ Equity | 392.814 | 476.456 | 82.143 | 44.198 | 52.024 |
Total Common Shares Outstanding | 26.372 | 26.192 | 15.138 | 10.719 | 10.656 |
Long Term Investments | 0.515 | 0.263 | 0.288 | ||
Long Term Debt | 40.633 | 13.845 | 14.995 | 9.911 | |
Current Port. of LT Debt/Capital Leases | 22.474 | 1.25 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
流动资产总额 | 327.005 | 378.961 | 420.966 | 438.038 | 469.996 |
现金和短期投资 | 319.678 | 370.492 | 413.88 | 433.574 | 466.839 |
现金等价物 | 319.678 | 370.492 | 413.88 | 433.574 | 466.839 |
应收账款总额,净额 | 3.691 | 3.367 | 2.015 | 2.163 | 2.007 |
Accounts Receivable - Trade, Net | 3.691 | 3.367 | 2.015 | 2.163 | 2.007 |
Prepaid Expenses | 3.636 | 5.102 | 5.071 | 2.301 | 1.15 |
Total Assets | 341.988 | 392.814 | 434.536 | 448.813 | 481.468 |
Property/Plant/Equipment, Total - Net | 12.775 | 11.261 | 10.826 | 9.748 | 10.117 |
Property/Plant/Equipment, Total - Gross | 17.255 | 15.517 | 14.772 | 13.405 | 13.487 |
Accumulated Depreciation, Total | -4.48 | -4.256 | -3.946 | -3.657 | -3.37 |
Long Term Investments | 0.131 | 0.515 | 0.67 | 0.92 | 1.248 |
Other Long Term Assets, Total | 2.077 | 2.077 | 2.074 | 0.107 | 0.107 |
Total Current Liabilities | 107.306 | 99.537 | 118.239 | 70.769 | 53.333 |
Accounts Payable | 10.014 | 10.058 | 8.265 | 10.084 | 5.597 |
Accrued Expenses | 19.97 | 23.523 | 33.876 | 37.614 | 26.675 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 24.26 | 22.474 | 18.482 | 5 | 3.125 |
Other Current Liabilities, Total | 53.062 | 43.482 | 57.616 | 18.071 | 17.936 |
Total Liabilities | 157.239 | 164.603 | 175.41 | 143.165 | 128.861 |
Total Long Term Debt | 39.235 | 40.633 | 42.345 | 56.309 | 58.147 |
Long Term Debt | 39.235 | 40.633 | 42.345 | 56.309 | 58.147 |
Other Liabilities, Total | 10.698 | 24.433 | 14.826 | 16.087 | 17.381 |
Total Equity | 184.749 | 228.211 | 259.126 | 305.648 | 352.607 |
Common Stock | 0.026 | 0.026 | 0.026 | 0.026 | 0.026 |
Additional Paid-In Capital | 583.382 | 575.675 | 567.927 | 560.365 | 552.743 |
Retained Earnings (Accumulated Deficit) | -398.659 | -347.49 | -308.827 | -254.743 | -200.162 |
Total Liabilities & Shareholders’ Equity | 341.988 | 392.814 | 434.536 | 448.813 | 481.468 |
Total Common Shares Outstanding | 26.407 | 26.372 | 26.349 | 26.327 | 26.319 |
- 年度
- 每季度
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
净收入/起跑线 | -203.674 | -72.148 | -25.991 | -21.785 | -10.902 |
经营活动产生的现金 | -135.043 | -42.861 | -6.445 | -20.76 | -0.46 |
经营活动产生的现金 | 1.193 | 0.882 | 0.684 | 0.582 | 0.41 |
非现金物品 | 36.205 | 7.189 | 2.88 | 1.599 | 2.668 |
营运资金的变化 | 31.233 | 21.216 | 15.982 | -1.156 | 7.364 |
投资活动产生的现金 | -3.406 | -1.742 | -0.818 | 22.134 | 10.355 |
资本支出 | -3.406 | -1.742 | -0.818 | -1.478 | -0.251 |
其他投资现金流量项目,总计 | 0 | 23.612 | 10.606 | ||
融资活动产生的现金 | 48.016 | 436.145 | 41.907 | 10.204 | 6.998 |
股票的发行(报废),净额 | 1.417 | 436.145 | 36.962 | 0.332 | 1.348 |
债务的发行(退还),净额 | 46.599 | 0 | 4.945 | 9.872 | 5.65 |
现金净变化 | -90.433 | 391.542 | 34.644 | 11.578 | 16.893 |
已付现金利息 | 0.684 | 0.751 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -51.169 | -203.674 | -165.011 | -110.927 | -56.346 |
Cash From Operating Activities | -49.039 | -135.043 | -92.546 | -75.893 | -42.95 |
Cash From Operating Activities | 0.224 | 1.193 | 0.883 | 0.594 | 0.307 |
Non-Cash Items | 8.516 | 36.205 | 27.281 | 19.773 | 10.995 |
Cash Interest Paid | 0.169 | 0.684 | 0.173 | 0.173 | 0.169 |
Changes in Working Capital | -6.61 | 31.233 | 44.301 | 14.667 | 2.094 |
Cash From Investing Activities | -2.111 | -3.406 | -2.288 | -0.522 | -0.118 |
Capital Expenditures | -2.111 | -3.406 | -2.288 | -0.522 | -0.118 |
Cash From Financing Activities | 0.336 | 48.016 | 47.786 | 47.094 | 47.012 |
Issuance (Retirement) of Stock, Net | 0.336 | 1.417 | 1.187 | 0.495 | 0.413 |
Issuance (Retirement) of Debt, Net | 0 | 46.599 | 46.599 | 46.599 | 46.599 |
Net Change in Cash | -50.814 | -90.433 | -47.048 | -29.321 | 3.944 |
投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
---|---|---|---|---|---|---|
Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 16.0026 | 4239554 | 672057 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 8.5225 | 2257846 | -472616 | 2022-12-31 | LOW |
ARK Investment Management LLC | Investment Advisor | 7.5961 | 2012429 | -169274 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2255 | 1649315 | 32754 | 2022-12-31 | LOW |
Payne (Joseph E) | Individual Investor | 5.5868 | 1480097 | 5000 | 2022-11-23 | LOW |
Nikko Asset Management Co., Ltd. | Investment Advisor/Hedge Fund | 5.4696 | 1449060 | -10355 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.4637 | 1447503 | 113607 | 2022-12-31 | LOW |
Ultragenyx Pharmaceutical Inc | Corporation | 4.5295 | 1200000 | -200000 | 2021-10-25 | LOW |
Balyasny Asset Management LP | Hedge Fund | 3.7906 | 1004235 | 664852 | 2022-12-31 | HIGH |
Fidelity Management & Research Company LLC | Investment Advisor | 3.4358 | 910243 | -44082 | 2022-12-31 | LOW |
Woodline Partners LP | Hedge Fund | 2.8397 | 752331 | -125193 | 2022-12-31 | HIGH |
BofA Global Research (US) | Research Firm | 2.5892 | 685954 | 577968 | 2022-12-31 | LOW |
Chivukula (Padmanabh) | Individual Investor | 2.2249 | 589448 | -5000 | 2023-03-06 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6983 | 449939 | 33148 | 2022-12-31 | LOW |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.2402 | 328567 | -2938 | 2022-12-31 | LOW |
Citadel Advisors LLC | Hedge Fund | 1.1449 | 303306 | 112903 | 2022-12-31 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.1432 | 302861 | 159743 | 2022-12-31 | LOW |
Sassine (Andy H) | Individual Investor | 1.0354 | 274313 | 1068 | 2022-08-15 | LOW |
Goldman Sachs & Company, Inc. | Research Firm | 0.9932 | 263138 | -35493 | 2022-12-31 | MED |
Rafferty Asset Management LLC | Investment Advisor/Hedge Fund | 0.7899 | 209254 | -51726 | 2022-12-31 | MED |
交易計算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模(槓桿 x 投資):
開倉
平倉
做空 做多
Arcturus Therapeutics Holdings Inc. Company profile
关于 Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc.是一家处于后期阶段的全球临床信使核糖核酸(mRNA)药物公司。 公司专注于传染病疫苗的开发以及肝脏和呼吸道罕见疾病的重要机会。 除mRNA平台外,公司的脂质纳米粒子(LNP)递送系统LUNAR有可能实现多种核酸药物,其自我复制mRNA技术(Self-Transcribing and Replicating RNA(STARR),技术)有可能在较低剂量水平上提供更持久的RNA和持续蛋白表达。 该公司使用STARR技术处于开发阶段的产品是ARCT-021、ARCT-154和ARCT-165。 其基于STARR技术平台的COVID-19候选疫苗ARCT-021正在进行II期临床试验。 其LUNAR-FLU疫苗包括肝脏特许经营ARCT-810(LUNAR-OTC)和肺部特许经营ARCT-032(LUNAR-CF)。
Industry: | Biotechnology & Medical Research (NEC) |
10628 Science Center Dr Ste 250
SAN DIEGO
CALIFORNIA 92121-1132
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球500,000万多名交易者的一份子,选择利用Capital.com进行交易吧。